MedTrace Logo

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

NCT01238783 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-12-01

No results posted yet for this study

Summary

To assess safety and efficacy of AL-15469A 0.5% /AL-6515 0.3% Ophthalmic Suspension for treatment of bacterial conjunctivitis

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension

Topical ocular dosed 3 times per day for 3 days

DRUG

AL-15469A 0.5%

Topical ocular dosed 3 times per day for 3 days

DRUG

AL-6515 0.3%

Topical ocular dosed 3 times per day for 3 days

DRUG

Vehicle

Topical ocular dosed 3 times per day for 3 days

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238783 on ClinicalTrials.gov